SLC5A2 and Renal insufficiency: The PBPK model simulated 24-h urinary glucose excretion in patients with renal insufficiency to compare the hypoglycemic effects of four SGLT2 inhibitors, the model simulation results recommend ipragliflozin 50 mg qd in patients with normal renal function and patients with mild renal insufficiency, dapagliflozin 10 mg qd or canagliflozin 100 mg qd in patients with moderate renal insufficiency, and empagliflozin 10 mg qd in patients with severe renal insufficiency to achieve the lowest dose and the maximum therapeutic effect.